Lugano, Switzerland, June 11, 2019 – Helsinn Healthcare SA (“Helsinn”) filed a complaint with the Taiwan Intellectual Property Court against Nang Kuang Pharmaceutical Co. Ltd. (“Nang Kuang”) on June 10, 2019 for patent infringement of Helsinn’s Patent No. I342212 claiming a pharmaceutical formulation of palonosetron (INN) for injection.
Helsinn’s complaint seeks damages for infringement, including treble damages for willful infringement, and a permanent injunction to prevent the manufacture, use, offer for sale and sale of Nang Kuang’s OKmilon palonosetron (INN) injection product.
For the details of the litigation (including the rights and infringing facts Helsinn asserted and the technical comparison chart), please see contact details below:
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco, and China, as well as a product presence in approximately 190 countries globally.
8F, No. 555, Sec. 4, Zhongxiao E. Road
Taipei 11072, Taiwan, R. O. C.
Tel: 886-2-2763-8000 ext. 2177